Chris Coffin is a partner with Pendley, Baudin & Coffin, L.L.P., located in New Orleans, Louisiana, and has years of experience litigating complex cases involving defective pharmaceutical products and medical devices. Mr. Coffin has been a leader in multiple MDL actions throughout the United States. Most recently, he was appointed as Co-Lead Counsel in the In re: Benicar (Olmesartan) Products Liability Litigation, pending in the District of New Jersey. In addition, he has served as Co-Lead Counsel in two other MDL cases involving pharmaceutical products: In re: Celexa and Lexapro Products Liability Litigation, in the Eastern District of Missouri, and In re: Celexa and Lexapro Marketing and Sales Practices Litigation, in the District of Massachusetts. He has also served as Co-Lead Counsel in a non-pharmaceutical products MDL, In re: Atlas Roofing Products Liability Litigation, in the Northern District of Georgia. In addition, Mr. Coffin has served as a court-appointed member of the Plaintiffs’ Steering Committee in the following pharmaceutical and medical device MDL cases: In re: Paxil Products Liability Litigation, in the Central District of California; In re: Zoloft Products Liability Litigation, in the Eastern District of Pennsylvania; In re: Effexor Products Liability Litigation, in the Eastern District of Pennsylvania; In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, in the District of Minnesota; and In re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Product Liability Litigation, in the District of South Carolina.
In addition to his legal education and experience, Mr. Coffin has been a registered nurse for over twenty (20) years. He has been licensed as a registered nurse in Ohio, Georgia, Maryland and Virginia, and he currently maintains his license in the State of Louisiana. Throughout his years of education and experience in nursing, Mr. Coffin has formally studied pharmacology, epidemiology, anatomy, physiology and pathophysiology.
Mr. Coffin filed the first Benicar (olmesartan) case in the country on January 13, 2014, the von Eberstein case, and has been litigating olmesartan cases since that time. Over the last year, he has dedicated a significant amount of his time and resources to educating other plaintiffs’ lawyers about the law and science related to the Benicar (olmesartan) litigation through multiple presentations at national litigation conferences.